July 7, 2022 -
TORONTO, CANADA – (July 7, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has been selected for a “Top Innovation in Wound Care 2022” Award from Wound Management & Prevention (WMP) Journal for its MolecuLightDX™
… Read MoreJune 29, 2022 -New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect Clinically Significant Bacteria that Impedes Wound Healing
TORONTO, CANADA – (June 29, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion
… Read MoreJune 14, 2022 -Contract Awarded for Products that Bring Improvement to the Health Care Industry
PITTSBURGH, PA – (June 14, 2022) MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with Premier, Inc. – a
… Read MoreJune 1, 2022 -Authors of International Consensus Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management
Toronto, CANADA and London, UK – (June 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced
… Read MoreApril 6, 2022 -KOVE Inc. to Distribute the MolecuLight Product Suite to Large South Korean Wound Care Market
Toronto, CANADA and Seoul, SOUTH KOREA – (April 6, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, and KOVE Inc., announce that the MolecuLight
… Read MoreMarch 1, 2022 -Wide-Spread Clinical Evidence using the MolecuLight i:X Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care
Toronto, CANADA and Abu Dhabi, UNITED ARAB EMIRATES – (March 1, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces
… Read MoreFebruary 24, 2022 -8 Clinical Posters and a Presentation and Hands-On Workshop Highlights the Breadth of Clinical Benefits of the MolecuLight Device for Wound Care Applications
Toronto, ONTARIO and Philadelphia, PENNSYLVANIA – (February 24, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads,
… Read MoreJanuary 18, 2022 -Authors Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change Contemporary Paradigms of Post-Surgical Wound Management
TORONTO, ONTARIO – (Jan. 18, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of “Uncovering
… Read MoreJanuary 4, 2022 -
DALLAS, TEXAS and TORONTO, ONTARIO – (Jan. 4, 2022) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that SWK Holdings Corporation has provided $10M USD structured debt to support MolecuLight’s global commercial expansion. SWK Holdings Corporation (Nasdaq: SWKH) is
… Read More
MolecuLight is SOC ll®
Type l Accredited:
MolecuLight awarded
Premier’s
Technology
Breakthrough Designation
MolecuLight
i:X
is designated as a:
MolecuLight included
in ISWCAP Consensus
Guidelines:
MolecuLight is a proud
corporate member of:
©2026
The MolecuLight® i:X and MolecuLightDX™ Imaging Devices are approved by Health Canada for sale in Canada and has CE marking for sale in the European Union.
The MolecuLight™ i:X and DX Imaging Devices have received FDA clearance.